Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Observational Study Assessing the Biosimilar of Ustekinumab in Active Mucocutaneous Behçet's Syndrome Refractory or Intolerant to Conventional Approaches

NCT07244614 is registered in ClinicalTrials.gov with Groupe français d'étude des Maladies Inflammatoires de loeil as lead sponsor.

NCT NCT07244614
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07244614 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Observational Study Assessing the Biosimilar of Ustekinumab in Active Mucocutaneous Behçet's Syndrome Refractory or Intolerant to Conventional Approaches
Lead sponsor
Groupe français d'étude des Maladies Inflammatoires de loeil
Phase
Observational
Overall status
Recruiting
Start date
September 1, 2025
Completion date
December 31, 2029
Enrollment
208 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

behçet's syndrome (bs)